Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC
Clinical trial NCT05513573 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05513573
- Sponsor
- Shanghai Henlius Biotech
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-14
- Primary completion
- 2024-09-30
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.